Xencor stock price
NASDAQ:XNCR · Nasdaq · Healthcare · sector #15Xencor's chart data is dated 2026-11-10. Recorded technical signals: 52-week high, MA aligned. There are 8 published signal records.
- Xencor's 52-week range runs from $10.38 to $40.08. The latest close of $39.39 is near the top of that range (−1.7% from the high).
- By close, the price moved +59.9% over 1 month, +78.2% over 3 months, +216.6% over 6 months.
- Technical signals currently flagged: 52-week high, MA aligned.
Xencor Talk · Newest
For account, order or payment questions, please send a 1:1 inquiry · 1:1 inquiry →
Loading Talk…
Xencor last closed at $39.39 (+2.07%) on 2026-11-10. Signals today: 52-week high, MA aligned. Listed on Nasdaq. Trailing 12 months PER is -25.7×. Its overall grade ranks 16 of 729 stocks in Healthcare.
Xencor overview
Xencor is listed on Nasdaq and classified in the Healthcare sector. Its market capitalization is about $2.81B. PER -25.7× and PBR 5.40× on the latest published figures. Trading records run from 2025-11-12 to 2026-11-10, a full year or more.
Revenue shrank from $165M in 2022 to $110M in 2024 (−33%). The company reported an operating loss of −$199M in 2024.
From 2026-09-01 to 2026-11-10 8 signals were recorded; 52-week high breakout appeared most often (4), and the latest was 52-week high breakout on 2026-11-10. Of the 2 signals with a 20-trading-day result, 1 ended higher and the average move was +2.5%. This is past data and does not indicate what comes next.
Position within its sector
Among 729 stocks in Healthcare, Xencor ranks No. 16 on the overall grade (A+), within the top 2% of its sector.
By factor, price momentum (A+, top 1%) and growth (A+, top 5%) stand out the most, while valuation (F, top 90%) is the weakest of the 5.
Grades are relative positions within the same sector, shown for reference only.
About this company
Xencor is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics to treat cancer and autoimmune diseases. Xencor develops and advances XmAb drug candidates and biotherapeutic drug candidates. Xencor focuses its business, research, and clinical efforts on developing and advancing a portfolio of XmAb drug candidates in oncology and autoimmune diseases.
Quantus's relationship data lists competitors: Roche, Amgen, Genmab and 3 more; customers: Amgen, AstraZeneca, Novartis and 2 more.
By revenue it ranks No. 265 of the 534 companies with revenue data in Healthcare, with less than 0.1% of the sector's total revenue.
The sector is fragmented: its top three companies hold 37.1% of revenue.
Source: 10-K FY2025 · SEC, business description (filed 2026-02-25)
Reported results
Position in sector
Healthcare · Overall A+ · 16/729
Valuation grade F
ETFs holding this stock
Virtus LifeSci Biotech Clinical Trials ETF
Details →About Xencor
- What technical signals does Xencor (XNCR) have?
- Xencor current technical signals: MA alignment (score 0.98).
- What published figures are available for Xencor?
- Market cap: $2.81B. Trailing 12 months PER: -25.7×. Latest quarter PBR: 5.40×. Dividend yield: 0.00%.
Like these rules? Backtest them.
Run this signal on this ticker in the free backtest builder — same window, no install.
Backtest this rule ↗Major stocks in the same sector
2026-11-10 dataset
Turn what you saw on this name into a strategy
Ask Q about Xencor, or open the plan table on the main site.
Ask Q about Xencor.
From the names you found to a trading rule
Tell Q about the stocks you found to place orders with your conditions.